Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Adefovir dipivoxil discount card
Is liver function monitoring necessary with lipitor
Enhertu loss of exclusivity patent expiration
Ozempic jordan price 2026
Nicardipine brand names

Xtandi+patent?

See the DrugPatentWatch profile for Xtandi

Xtandi® (enzalutamide) and its Patent Landscape

Item Detail
Drug Enzalutamide (Xtandi)
Indication Metastatic castration‑resistant prostate cancer (mCRPC)
Manufacturer Janssen Pharmaceuticals (a Johnson & Johnson company)
Approval Dates U.S. FDA: 2014 (mCRPC) – 2020 (non‑metastatic CRPC)
Patent Family (key patents) • WO 2007/032345 – “Enzalutamide and its use for the treatment of prostate cancer” (first disclosed 2007).
• US 7,642,352 – “Enzalutamide and compositions thereof” (filing 2005).
• WO 2008/022749 – “Synthesis of enzalutamide and analogs”.
• US 2008/0268572 – “Methods of treating prostate cancer with enzalutamide.”
Patent Expirations (U.S.) • US 7,642,352 – 2021 (expired).
• US 2008/0268572 (publication) – 2024 (actual utility patent 2023).
• Key remaining patents (e.g., formulation, combination therapy) run through 2025–2030 depending on the claim set and secondary patents.
Current Status • Janssen holds the core utility patents and many formulation/composition patents.
• Generic manufacturers (e.g., Teva, Mylan) have filed for FDA approval (ANDA filings) but are still awaiting patent clearance.
• In many countries, patents on the core API have expired (e.g., U.K., EU 2022), allowing generic competition there.
Generic Entry in the U.S. • The first FDA approval of a generic enzalutamide (no‑brand) is expected around 2025–2026 after all patents expire and the ANDA is cleared.
Patent Strategy Highlights 1. Patent “evergreening”: Janssen has filed secondary patents on new salt forms, sustained‑release formulations, and combination therapies (e.g., with taxanes) to extend exclusivity.
2. Method claims: patents on “using enzalutamide to treat a specific subtype of prostate cancer” or “combining with a specific hormonal agent” have extended market protection.
3. International portfolio: Many patents are still active in emerging markets (India, China, Brazil) where the drug remains brand‑exclusive.

What does this mean for patients and prescribers?

Scenario What you can expect
In the U.S. (2025‑2026) Generic versions may become available, potentially lowering cost dramatically.
Outside the U.S. (post‑2022 in EU/UK) Generic competition is already active; prices may be lower.
For combination therapies Janssen still holds patents on certain combos (e.g., enzalutamide + docetaxel) which could delay generic entry for those specific regimens.

Quick FAQ

Question Short Answer
When did the first patent on enzalutamide file? 2005 (US 7,642,352).
When will the core US patents expire? 2021 (first core) → 2024 (next core) → 2025‑2030 for secondary claims.
Will generics be available soon? Likely 2025‑2026 in the U.S., earlier in many other markets.
Does Xtandi still have exclusivity? For the core drug and some combination/formatting claims, yes—through 2030 in the U.S.
Are there any “orphan” patents? No, because prostate cancer is not an orphan disease.

Bottom line

  • Xtandi is still protected by a mix of core and secondary patents in the U.S.; generics are on the horizon but will only enter once those patents expire.
  • In many other regions, the core patents have already expired, and generic versions are circulating.
  • Janssen’s patent portfolio focuses on formulation, salt forms, and combination methods, which are the usual ways to extend market exclusivity for a blockbuster drug.

Let me know if you need more details on a specific country, the status of a particular patent, or how this might impact pricing or insurance coverage!



Other Questions About Xtandi :

Xtandi patent expiry? Xtandi generic release date? Xtandi loe? Xtandi patent expiration? When does xtandi go generic? Xtandi patent expiration date? Xtandi loss of exclusivity?